ANTECEDENTES. Algunos datos recientes sugieren que la prevalencia del genotipo 4 del virus de la hepatitis C (VHC) se ha incrementado en España en los últimos años. OBJETIVO. Poner de manifiesto cambios en la prevalencia de los genotipos del VHC en España durante los últimos 9 años. MÉTODOS. Se amplificó un fragmento del genoma del VHC presente en 3.161 muestras de suero tomadas de individuos positivos para anti-VHC no seleccionados. Después se identificó el genotipo mediante una prueba de hibridación reversa (line probe assay, LiPA). Las muestras procedían de 17 regiones diferentes y se tomaron entre enero de 1996 y diciembre de 2004. RESULTADOS. La prevalencia global de genotipos del VHC fue: 1b, 41,3%; 1a, 24,1%; 3, 19,6%; 4, 11,6%; 2, 3,1%; y 5, 0,3%. Considerando la edad de los pacientes, las prevalencias de los genotipos 1a, 3 y 4 fueron significativamente mayores entre los nacidos después de 1950, en tanto que la del genotipo 1b fue menor. Estas diferencias significativas se observaron también al considerar sólo a los pacientes sin factores de alto riesgo conocidos. Los incrementos significativos en las prevalencias de los genotipos 1a y 3 se encontraron al comparar entre sí a los pacientes nacidos en 1941-1950 con los nacidos en 1951-1960. Para el genotipo 4, este hallazgo se produjo, sin embargo, al comparar estos últimos con los nacidos en 1961-1970. CONCLUSIONES. En España parecen haber sucedido dos episodios recientes de importación de cepas del VHC. El primero supuso la diseminación de cepas de los genotipos 1a y 3. El segundo fue más reciente y supuso la introducción de cepas del genotipo 4.
Introduction
Hepatitis C virus (HCV) strains are grouped into six main genotypes, namely genotypes 1 to 6, and into several subtypes within most of them 1 . Genotype 1a prevails . Two main episodes of spread of HCV are thought to have occurred in Europe: the former one involved the spread of genotype 1 strains through blood transfusion, and the second followed the introduction of genotype 3 strains through the use of injection drugs 2 . Genotype 1b has been found prevalent in all studies performed on unselected chronic carriers from Spain, always reaching figures above 50% [4] [5] [6] [7] . Genotype 3 prevalence ranged from 4 to 17%, rising above 20% among injection drug users [4] [5] [6] [7] [8] . Prevalence of genotype 4 has been usually found below 10%, but higher figures have been recorded among injection drug users [9] [10] [11] . These data suggest that the import of genotype 3 strains into Spain would have been accompanied by the introduction and spread of genotype 4. The aim of the present work was to assess changes in the prevalence of HCV genotypes in Spain along the period 1996-2004.
Materials and methods
The study was retrospective in nature and included 3161 individual, HCV RNA-positive serum samples from HCV carriers sent to a reference laboratory for genotype identification prior to antiviral treatment. Samples from patients suspected to have been involved in epidemic outbreaks of HCV infection were not included, and no additional selection in regard to age, sex, geographical origin, other risk Samples came from 58 health care institutions (21 reference hospitals, 28 regional hospitals, four transfusion centres, four private institutions and one reference laboratory) from 17 different regions of Spain (table 1) and were taken between January, 1996 and December, 2004. Most samples (2743, 90.9%) were from eight regions contributing with more than 100 samples each. Infection by human immunodeficiency virus (HIV) and/or history of intravenous drug use (IVDU) was notified in 509 cases (group 1). Among the remaining, 29 samples were from children born from HCV-infected mothers (group 2); 98 were from immigrants (group 3); and 2379 were from adults native from Spain (group 4). The gender was known from all patients but eight, with a predominance of men (67.8%). Age was known from 2014 patients (66.8%), and ranged from newborn age to 89 years old.
A fragment of the 5Ј non-coding region of the HCV genome was amplified by the polymerase chain reaction (PCR) 6 from all samples, and the genotype was determined by reverse hybridisation (line probe assay, LiPA), using a commercial test (Versant HCV GenoAmp LiPA, Bayer Healthcare LLC, Tarytown, NY, USA). Prevalence of genotypes 1a, 1b, 2, 3, 4, 5 and 6 was calculated, and results from samples grouped by different criteria were compared by the chi square (chi 2 ) test. Differences were considered statistically significant for p < 0,01.
Results
HCV genotype 1 strains present in 146 samples displayed hybridisation patterns that did not allow a genosubtype assignation, and were excluded from the analysis. These samples accounted for 4.6% of the total and were almost uniformly distributed along the period of the study (range: 4.1 to 4.8% per year). Table 2 summarises the results obtained on the remaining 3015 samples, according to the four groups of patients studied. Table 3 details those corresponding to immigrants in regard to the region of origin. Genotypes 1a, 3 and 4 were significantly more prevalent among patients from group 1 in comparison with those from group 4. Prevalence of genotype 2 was significantly higher among immigrants from the tropics of Africa in comparison with the remaining patients (22.2% vs 2.9%; chi 2 = 27.62, p < 0,01). Figure 1 shows the overall prevalence of HCV genotypes on patients grouped by the year of sampling. Genotype 1b was always the more prevalent, but its overall prevalence was just 41.3%. Since a increasing trend was observed for the overall prevalence of genotypes 1a and 4, a comparison was done with samples grouped into two periods of time (1996-2000 and 2001-2004) (table 4) . A significant increase of the prevalence of genotype 4 was found, together with a decrease of the prevalence of genotype 1b. Table 5 shows the prevalence of HCV genotypes in regard to the year of birth of the patients. Genotype 1b was significantly more prevalent among those born before 1951, and the prevalence of genotypes 1a, 3 and 4 was significantly higher among patients born after 1950 (table 6) . Similar findings in regard to age were found among adult patients lacking notified HIV infection and history of IVDU (tables 7 and 8). Among the latter, a significant switch-up of the prevalence of genotypes 1a and 3 was observed among patients born in [1951] [1952] [1953] [1954] [1955] [1956] [1957] [1958] [1959] [1960] 
Discussion
Data regarding prevalence of HCV genotypes in Europe suggest that genotype 3 produced a recent epidemic of HCV infection among the injection drug users and spread subsequently to other population groups that had been already penetrated by genotype 1 strains, mainly by genotype 1b, in the past 2, [12] [13] [14] . The present investigation is affected by limitations that are characteristic of retrospective studies, such as the presence of uncontrolled sampling variations from year to year, the lack of representativity of the sample in terms of population, or the risk of underreporting of relevant epidemiological data for the patients included. With these limitations in mind, the results show that Spanish HCV carriers born before 1951 are mainly infected by genotype 1b. In addition, they show that genotype 1a and 3 strains are significantly more frequent among patients born after 1950, and confirm the high prevalence of these genotypes among patients displaying significant risk factors, such as HIV co-infection or history of IVDU. Since the acquisition of the HCV infection is very uncommon before the age of 20, this is consistent with the introduction, 20-30 years ago, of genotype 1a and 3 strains into the IVDU population and with its spread to other population groups. Evidence for such introduction of HCV genotype 1a together with genotype 3 has been also reported from other European countries [12] [13] [14] . In agreement with prior findings [9] [10] [11] , the age-specific patterns of prevalence found for genotype 4 indicate that this HCV genotype has been also introduced recently in Spain. They suggest, in addition, that the import of this genotype was independent of the import of genotypes 1a and 3 and happened around 10 years later. In support of this interpretation, an increasing prevalence of genotype 4 among the youngest HCV carriers have been reported from Italy [15] [16] [17] , and a significant association of this genotype with infections acquired after 1990 has been found in Austria 18 . It seems very likely that introduction of genotype 4 into Europe and the United States has been related with injection drug use 15, 19, 20 , and the findings of this investigation agree with this proposal. The significant increase in prevalence of genotype 4 found among patients without notified high risk factors born after 1960 suggest, in addition, that this genotype begun to spread to other population groups at the beginning of the 80's decade.
The diversification observed for genotypes 1 and 2 in Africa 21 and the geographical distribution found for genotypes 4 and 5 lead to suggest an African origin for all these four HCV genotypes. Import of African strains of hepatitis B virus (HBV) into Spain has been recently do- 
